Muscular dystrophy is a genetic condition, and no lifestyle change, diet, or exercise routine can prevent it from occurring. The mutations that cause muscular dystrophy are written into a person’s DNA, either inherited from a parent or arising spontaneously. About one-third of Duchenne muscular dystrophy cases, the most common and severe form, result from brand-new (de novo) mutations with no family history at all. That said, for families who know they carry a muscular dystrophy gene, there are real options to reduce the chance of passing it to a child.
Why Lifestyle Changes Can’t Prevent It
Muscular dystrophies are caused by mutations in more than 40 different genes. These mutations lead to missing or defective proteins in muscle cell membranes, which causes progressive muscle weakness and loss. Because the root cause is genetic, not environmental, there is nothing you can eat, drink, or do physically to stop the condition from developing in someone who carries the mutation. A balanced diet rich in fruits, vegetables, lean proteins, and healthy fats can support overall muscle health and may help slow some aspects of muscle wasting once a diagnosis exists, but it does not change the underlying genetic code.
This distinction matters because families sometimes feel guilt or wonder if something they did caused their child’s condition. It’s important to understand that muscular dystrophy is not the result of anything a parent did or failed to do during pregnancy or childhood.
How Muscular Dystrophy Is Inherited
There are three main inheritance patterns, and knowing which one applies to your family shapes every decision about screening and family planning.
- X-linked recessive: The most well-known pattern, responsible for Duchenne and Becker muscular dystrophy. The mother carries the faulty gene on one of her X chromosomes. Because boys have only one X chromosome, they develop the condition if they inherit that copy. Girls who inherit it typically become carriers, though some show mild symptoms.
- Autosomal dominant: Only one copy of the mutated gene, from either parent, is enough to cause the condition. Facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy follow this pattern. Both males and females are affected equally.
- Autosomal recessive: Both parents must carry and pass on a faulty copy. A child who inherits just one copy is an unaffected carrier. Limb-girdle muscular dystrophy includes several subtypes that follow this pattern.
The complexity doesn’t end there. Even within the same family carrying the same mutation, severity can vary widely. Genetic counselors describe this as “variable expressivity,” and it makes predicting outcomes and explaining risks to families especially challenging.
Carrier Screening and Blood Tests
For Duchenne muscular dystrophy specifically, carrier screening can identify women who carry the gene mutation before they ever become pregnant. The process often starts with a simple blood test measuring creatine kinase (CK), an enzyme that leaks out of damaged muscle cells. In women aged 20 to 50, a CK level above 200 U/L is flagged as elevated. If your level comes back high, you’ll be asked to avoid strenuous exercise for two weeks and then retest. If it remains above 200 U/L, genetic testing of the dystrophin gene follows.
The genetic testing itself happens in stages. First, a technique called MLPA checks for large deletions or duplications across the gene’s 79 sections (exons). If that comes back normal, next-generation sequencing scans the entire gene for smaller mutations. Women with a family history of Duchenne are offered genetic testing regardless of their CK level, because some carriers have completely normal CK readings and would otherwise be missed.
Carriers who are identified as “asymptomatic” have the gene mutation but no muscle weakness, no difficulty walking or climbing stairs, and no cardiac symptoms. However, some carriers do develop mild muscle or heart problems over time, so knowing your status has health implications beyond family planning.
Genetic Counseling
If you have a family history of any form of muscular dystrophy, or if you’ve already had a child diagnosed with it, genetic counseling is the single most useful step you can take. A genetic counselor can map your family’s specific mutation, explain the odds of passing it on, and walk you through every reproductive option available.
This is especially valuable because the relationship between a specific gene mutation and how the disease actually manifests is complex and has become more so as new therapies have emerged. Some mutations in the dystrophin gene lead to severe Duchenne muscular dystrophy, while others cause the milder Becker form, and predicting which outcome a given mutation produces requires specialized expertise. Genetic counselors are trained to interpret these patterns and translate them into practical guidance for families making reproductive decisions.
Preimplantation Genetic Testing With IVF
For couples who know they carry a muscular dystrophy mutation, preimplantation genetic testing (PGT) combined with in vitro fertilization offers a way to select embryos that don’t carry the mutation before pregnancy begins. The process requires knowing the family’s specific mutation in advance, because the genetic analysis is tailored to that exact change in the DNA.
During IVF, eggs are fertilized in a lab and allowed to develop for several days. A few cells are then biopsied from each embryo and tested for the family’s mutation. Embryos can also be screened for chromosomal abnormalities at the same time. Only unaffected embryos are transferred to the uterus.
In one documented case of a couple carrying a Duchenne mutation, eight embryos were biopsied across four IVF cycles. Two carried the mother’s mutation, one had a chromosomal abnormality, and five were normal. A single healthy embryo was transferred and resulted in a successful pregnancy. This illustrates both the promise and the reality of the process: it works, but it often requires multiple cycles and produces a mix of affected and unaffected embryos.
Prenatal Testing During Pregnancy
If you’re already pregnant and concerned about muscular dystrophy, two procedures can test the fetus directly. Chorionic villus sampling (CVS) can be done between weeks 10 and 12 of pregnancy. A small sample of placental tissue is collected either through the cervix or through the abdomen with a needle, and the fetal DNA is analyzed for the known family mutation.
Amniocentesis is the other option, typically performed later in pregnancy, around 15 to 20 weeks. It involves drawing a small amount of amniotic fluid. Both tests carry a small risk of miscarriage, and neither can be done before 10 weeks or after 13 weeks (for CVS) without reduced accuracy or increased risk.
These tests are diagnostic, not screening tools. They’re used when a specific mutation has already been identified in the family. The results give families information to prepare, whether that means arranging early interventions, connecting with specialist care teams, or making difficult personal decisions about the pregnancy.
The One-Third Problem: Spontaneous Mutations
Even with perfect screening, about one-third of all Duchenne cases arise from new mutations that neither parent carries. These spontaneous changes happen during the formation of the egg or sperm, or very early in embryonic development. No amount of genetic testing before conception can predict these events, because the mutation doesn’t exist in either parent’s DNA.
Germline mosaicism adds another layer of complexity. In these cases, a parent carries the mutation in some of their egg or sperm cells but not in their blood cells, so standard genetic testing of the parent comes back negative. This means that even after having one child with a “spontaneous” mutation, there can still be a meaningful chance of it happening again in a future pregnancy. Genetic counselors factor this possibility into their risk calculations for families who have already had an affected child.
Newborn Screening
Early detection doesn’t prevent muscular dystrophy, but it changes outcomes. Children diagnosed before symptoms appear can start supportive therapies earlier, which helps preserve muscle function longer. Duchenne muscular dystrophy has been recommended for addition to the U.S. Recommended Uniform Screening Panel, which would make it part of the routine blood test given to every newborn. Implementation varies by state, and it will take time before screening is universally available. For now, if you have a family history, requesting early genetic testing through your pediatrician remains the most reliable path to an early diagnosis.